Toby Ferguson, MD, PhD, CMO of Voyager Therapeutics, discusses his transition from Biogen to Voyager, biomarker-driven drug development and the company’s approach to receptor-mediated drug delivery approach.
Toby Ferguson, MD, PhD, CMO of Voyager Therapeutics, discusses his transition from Biogen to Voyager, biomarker-driven drug development and the company’s approach to receptor-mediated drug delivery approach.